PMID- 28137500
OWN - NLM
STAT- MEDLINE
DCOM- 20180108
LR  - 20220408
IS  - 1532-3064 (Electronic)
IS  - 0954-6111 (Linking)
VI  - 123
DP  - 2017 Feb
TI  - Interstitial lung disease and myositis-specific and associated autoantibodies: 
      Clinical manifestations, survival and the performance of the new ATS/ERS criteria 
      for interstitial pneumonia with autoimmune features (IPAF).
PG  - 79-86
LID - S0954-6111(16)30342-0 [pii]
LID - 10.1016/j.rmed.2016.12.014 [doi]
AB  - OBJECTIVE: to describe the clinical manifestations and survival of patients with 
      ILD and myositis-specific and associated autoantibodies, and to evaluate the 
      performance of the new ATS/ERS classification criteria for IPAF. PATIENTS AND 
      METHODS: Patients with ILD and positive in at least one of the following 
      autoantibodies: anti-Jo-1, anti-Ej, anti-PL7, anti-PL 12, anti-PM/SCL 75 and 
      anti-PM/SCL100 were included. Patients were separated into three groups according 
      to their autoantibody profile: 1. Jo-1 positive patients, 2. Non-Jo-1 
      antisynthetase autoantibody positive patients, and 3. PM/SCL positive patients. 
      Relevant clinical characteristics were registered. Patients were evaluated had 
      they fulfilled Bohan and Peter's criteria (BPC) for inflammatory myopathies. We 
      evaluated the performance of the IPAF ATS/ERS proposal to classify as such the 
      patients that did not fulfilled BPC, and evaluated whether IPAF patients had a 
      worse survival that BPC patients. RESULTS: Sixty-eight patients were included. 
      Jo-1 was the most frequent autoantibody (65%), followed by non Jo1 
      anti-synthetase autoantibodies (31%). Non-Jo1 patients had lower Creatin Kinase 
      serum levels at the baseline and less frequency of arthritis. Only 50% of 
      patients fulfilled BPC. All patients not complying with BPC did comply with IPAF 
      criteria. There was no difference in survival between IPAF and BPC patients. Anti 
      Jo-1 positive was associated to survival and the extent of lung inflammation was 
      associated to mortality. CONCLUSIONS: Patients differ in clinical manifestations 
      according to the autoantibody profile. All patients not complying with BPC did 
      comply with the new IPAF criteria. There was no difference in survival between 
      BPC and IPAF patients. Jo-1 patients had a better survival. Extent of lung 
      inflammation was associate to mortality.
CI  - Published by Elsevier Ltd.
FAU - Mejia, Mayra
AU  - Mejia M
AD  - Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de 
      Enfermedades Respiratorias, Ismael Cosio Villegas, Mexico.
FAU - Herrera-Bringas, Denisse
AU  - Herrera-Bringas D
AD  - Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de 
      Enfermedades Respiratorias, Ismael Cosio Villegas, Mexico.
FAU - Perez-Roman, Diana I
AU  - Perez-Roman DI
AD  - Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, 
      Venezuela.
FAU - Rivero, Hermes
AU  - Rivero H
AD  - Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, 
      Venezuela.
FAU - Mateos-Toledo, Heidegger
AU  - Mateos-Toledo H
AD  - Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de 
      Enfermedades Respiratorias, Ismael Cosio Villegas, Mexico.
FAU - Castorena-Garcia, Pedro
AU  - Castorena-Garcia P
AD  - Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de 
      Enfermedades Respiratorias, Ismael Cosio Villegas, Mexico.
FAU - Figueroa, Jose E
AU  - Figueroa JE
AD  - Instituto Nacional de Enfermedades Respiratorias, Ismael Cosio Villegas, Mexico.
FAU - Rojas-Serrano, Jorge
AU  - Rojas-Serrano J
AD  - Programa de Maestria y Doctorado en Ciencias Medicas, Facultad de Medicina, 
      Universidad Nacional Autonoma de Mexico, Mexico. Electronic address: 
      jrojas@iner.gob.mx.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20161223
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Autoantibodies)
RN  - 0 (Biomarkers)
RN  - 0 (Jo-1 antibody)
SB  - IM
MH  - Adult
MH  - Antibodies, Antinuclear/blood
MH  - Autoantibodies/*blood
MH  - Autoimmune Diseases/diagnosis/diagnostic imaging/*immunology
MH  - Biomarkers/blood
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Diseases, Interstitial/diagnosis/diagnostic imaging/*immunology
MH  - Male
MH  - Middle Aged
MH  - Myositis/diagnostic imaging/*immunology
MH  - Prognosis
MH  - Severity of Illness Index
MH  - Tomography, X-Ray Computed
EDAT- 2017/02/01 06:00
MHDA- 2018/01/09 06:00
CRDT- 2017/02/01 06:00
PHST- 2016/08/02 00:00 [received]
PHST- 2016/12/19 00:00 [revised]
PHST- 2016/12/20 00:00 [accepted]
PHST- 2017/02/01 06:00 [entrez]
PHST- 2017/02/01 06:00 [pubmed]
PHST- 2018/01/09 06:00 [medline]
AID - S0954-6111(16)30342-0 [pii]
AID - 10.1016/j.rmed.2016.12.014 [doi]
PST - ppublish
SO  - Respir Med. 2017 Feb;123:79-86. doi: 10.1016/j.rmed.2016.12.014. Epub 2016 Dec 
      23.